• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures invests in Qkine – once again…
Dec 22 2022

Cambridge, UK: Qkine, an o2h Ventures portfolio company that produces high purity, animal free-growth factors, cytokines, and other complex proteins, closed its oversubscribed funding round at £4.3 million. The investors included o2h Ventures, Parkwalk , Downing, and Cambridge Angels.

Qkine combines proprietary protein production process development with protein engineering techniques to develop unique and exceptionally high-purity products that tackle fundamental biological and scale-up challenges for the fast-growing stem cell, organoid, regenerative medicine, and cellular agriculture sectors.

The funding round will enable the company to expand its research work with the new state of the art facility in Cambridge.  Additionally, it will enable them to grow their company internationally and meet demand on a worldwide scale.

Catherine Elton, CEO of Qkine, said:

“We’re delighted that o2h Ventures, an existing investor of Qkine, have supported the latest funding round.  Their deep biotechnology sector expertise, network, and the community they have built around the o2h portfolio companies have been a source of support during the early stages of our growth and will play an important role in helping us achieve scale and maximise international opportunities. This is an exciting time for the company as we build our team and establish our new HQ and manufacturing facility to facilitate our next phase of rapid growth, the relationships with our valued investors and advisors, like the o2h team, helps make the journey thoroughly enjoyable.”

Sunil Shah, CEO of o2h Ventures, said: 

We are excited to continue to back Qkine, a business in which we participated in the seed round and now continue to back as they scale into their A round.  An exciting, growing business targeting and expanding customer base with an amazing CEO and team.

About Qkine

Qkine manufactures high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications including stem cell and organoid culture. Based in Cambridge, UK, Qkine combines proprietary production processes with protein engineering technology to tackle fundamental biological, quality and scale-up challenges to provide more reliable tools for research and bio-manufacturing.

Qkine is an ISO 9001:2015 certified company with an established global distribution network. Please visit qkine.com for more information or follow us on LinkedIn for the latest company updates.

About o2h Ventures

The o2h Ventures ‘Human Health’ SEIS and Knowledge Intensive (KI) funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease.  The main focus of the investments is on the development of novel therapeutic treatments with a clear path to the clinic.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.  

For more information or to invest in the fund, please visit. 

Media Contact:

Juhi Shah

Marketing Manager

o2h Ventures

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
recent press releases
  • o2h Ventures backed Small Pharma unveils positive phaseIIa results Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 January, 2023
  • Kuano wins Innovate UK grant o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 January, 2023
  • o2h Ventures funds o2h Ventures invests in Qkine – once again… 22 December, 2022
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)